lemms personal page - To The Moon

lemms

lemms

No personal profile

12Follow

4Followers

0Topic

0Badge

2021-08-31

Regardless of the stock price, I do hope that this is finally a cure for Alzheimer disease. It is a crippling disease.

AC Immune shares surged more than 70% in early trading

2021-08-12

I like chewy, but hesitant about Roku. I had their box previously, but didn't find it useful. A cheap android box from huaqiangbei is more than enough to replace Roku.

2 Stocks to Buy When the Next Market Crash Comes

2021-08-12

If there is "if only...", then there will not be beggars...

Sorry, the original content has been removed

2021-08-10

Wow... Visa is going to be affected by this for sure.

Sorry, the original content has been removed

2021-03-08

Can we buy stocks that grow pot? I tried, but got rejected.

Canada eyes tighter rules for grow-your-own pot producers

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3562228884568927","uuid":"3562228884568927","gmtCreate":1599135270304,"gmtModify":1615256527965,"name":"lemms","pinyin":"lemms","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":12,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":3,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":818599234,"gmtCreate":1630417869628,"gmtModify":1676530298114,"author":{"id":"3562228884568927","authorId":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3562228884568927","authorIdStr":"3562228884568927"},"themes":[],"htmlText":"Regardless of the stock price, I do hope that this is finally a cure for Alzheimer disease. It is a crippling disease.&nbsp;","listText":"Regardless of the stock price, I do hope that this is finally a cure for Alzheimer disease. It is a crippling disease.&nbsp;","text":"Regardless of the stock price, I do hope that this is finally a cure for Alzheimer disease. It is a crippling disease.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/818599234","repostId":"1174676883","repostType":4,"repost":{"id":"1174676883","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630417268,"share":"https://ttm.financial/m/news/1174676883?lang=&edition=fundamental","pubTime":"2021-08-31 21:41","market":"us","language":"en","title":"AC Immune shares surged more than 70% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1174676883","media":"Tiger Newspress","summary":"AC Immune shares surged more than 70% in early trading.\n\n\nAC Immune SA and its collaborating partner","content":"<p>AC&nbsp;Immune&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;70%&nbsp;in&nbsp;early&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/9e1ae2e20dee3043b692297f3834cf6d\" tg-width=\"878\" tg-height=\"616\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><b>AC Immune SA</b>&nbsp;and its collaborating partner&nbsp;<b>Genentech</b>, part of&nbsp;<b>Roche Holdings AG</b>, have&nbsp;announced topline data&nbsp;from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).</li>\n <li>Semorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.</li>\n <li>Safety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.</li>\n <li>Semorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.</li>\n <li>There was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.</li>\n <li>Further analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.</li>\n <li>Semorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AC Immune shares surged more than 70% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAC Immune shares surged more than 70% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-31 21:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AC&nbsp;Immune&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;70%&nbsp;in&nbsp;early&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/9e1ae2e20dee3043b692297f3834cf6d\" tg-width=\"878\" tg-height=\"616\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><b>AC Immune SA</b>&nbsp;and its collaborating partner&nbsp;<b>Genentech</b>, part of&nbsp;<b>Roche Holdings AG</b>, have&nbsp;announced topline data&nbsp;from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).</li>\n <li>Semorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.</li>\n <li>Safety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.</li>\n <li>Semorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.</li>\n <li>There was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.</li>\n <li>Further analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.</li>\n <li>Semorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACIU":"AC Immune SA"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174676883","content_text":"AC Immune shares surged more than 70% in early trading.\n\n\nAC Immune SA and its collaborating partner Genentech, part of Roche Holdings AG, have announced topline data from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).\nSemorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.\nSafety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.\nSemorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.\nThere was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.\nFurther analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.\nSemorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.","news_type":1},"isVote":1,"tweetType":1,"viewCount":395,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894068067,"gmtCreate":1628778283459,"gmtModify":1676529852631,"author":{"id":"3562228884568927","authorId":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3562228884568927","authorIdStr":"3562228884568927"},"themes":[],"htmlText":"I like chewy, but hesitant about Roku.&nbsp;I had their box previously, but didn't find it&nbsp;useful. A cheap android box from huaqiangbei is more than enough to replace Roku.&nbsp;","listText":"I like chewy, but hesitant about Roku.&nbsp;I had their box previously, but didn't find it&nbsp;useful. A cheap android box from huaqiangbei is more than enough to replace Roku.&nbsp;","text":"I like chewy, but hesitant about Roku. I had their box previously, but didn't find it useful. A cheap android box from huaqiangbei is more than enough to replace Roku.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/894068067","repostId":"2158709252","repostType":4,"repost":{"id":"2158709252","pubTimestamp":1628772540,"share":"https://ttm.financial/m/news/2158709252?lang=&edition=fundamental","pubTime":"2021-08-12 20:49","market":"us","language":"en","title":"2 Stocks to Buy When the Next Market Crash Comes","url":"https://stock-news.laohu8.com/highlight/detail?id=2158709252","media":"Motley Fool","summary":"Planning your actions ahead of market crashes makes following through easier.","content":"<p><b>Roku</b> (NASDAQ:ROKU) and <b>Chewy</b> (NYSE:CHWY) are two excellent companies growing revenue and customers rapidly. Investors have noticed, and their stock prices are up 289% and 154%, respectively, over the last three years.</p>\n<p>One way you can get into these stocks at better prices would be during a stock market crash. Admittedly, it can be difficult to be a buyer when you see the market selling off. That's why it pays to look into companies you are interested in buying and put them on your list so that you can be ready to make the buy when the event occurs.</p>\n<p>Here are a few features of each stock that make these two companies attractive investments in the long run.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4cf59b52c0f0427b4b325944820d668\" tg-width=\"700\" tg-height=\"436\" referrerpolicy=\"no-referrer\"><span>Data source: YCharts</span></p>\n<h2>1. Roku</h2>\n<p>Roku is benefiting from the long-run secular trend where consumers are switching from linear TV to streaming viewership. The rate of the shift may fluctuate but it's unlikely to change direction. According to Roku management, eventually, content will be 100% streaming. Indeed, here is what founder and CEO Anthony Wood said in its most recent conference call:</p>\n<blockquote>\n But I think the big picture for me is that we're still in the middle of this transition where viewers, advertisers, and the industry is moving 100% to streaming. We're just not there yet, but it's moving and it's happening. If you look, <a href=\"https://laohu8.com/S/AONE.U\">one</a> stat I think that's interesting from Nielsen is that if you look at 18 to 45-year-olds, 39% of their TV watching is streaming.\n</blockquote>\n<p>Roku has accumulated 55.1 million accounts, a 28% increase from the second quarter of last year. Undoubtedly, the pandemic helped accelerate customer acquisition. Folks were limited in entertainment options when ballparks, concerts, restaurants, and movie theaters were all shut down for most of the previous year.</p>\n<p>The company's operating system is reliable and fast. That's led many original equipment manufacturers to build TVs with Roku's operating system natively installed. Roku is the No. 1 TV operating system in the U.S. and Canada, and it's well on its way to international expansion.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7a23631810a53cf2c4ddc7de5a5f41be\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>2. Chewy</h2>\n<p>Chewy is an exclusively online pet retailer. The company boasts 19.8 million active customers, 31.8% more than it had last year. The pandemic caused millions of pet parents to look for new options to fulfill their pet's everyday needs. Some may never return to shopping in brick-and-mortar stores. One reason is that Chewy offers customers automatic delivery of their pet's food and medicine.</p>\n<p>Indeed, in its most recent quarter, 69.3% of overall sales were through automatic delivery, or what Chewy calls Autoship. It makes people's lives easier as it is one less thing they need to remember. Chewy even offers a small discount on orders placed through Autoship. The company is piggybacking off the long-run spending moving online from retail locations.</p>\n<p>Revenue is growing rapidly, and Chewy is doing it efficiently. Its gross profit margin expanded from 16.6% in 2016 to 25.5% in 2021.</p>\n<h2>Investor takeaway</h2>\n<p>Roku and Chewy are doing an excellent job capturing their respective markets and solving a problem for their customers. Streaming content costs less, and viewers get liberated from lengthy cable contracts. Chewy gives pet parents the peace of mind to know food and medicine can be delivered automatically.</p>\n<p>The one hesitation investors could have with these two companies is their relatively rich valuations. Putting these stocks on your watch list and waiting for a market correction to buy could minimize that hesitation.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Stocks to Buy When the Next Market Crash Comes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Stocks to Buy When the Next Market Crash Comes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-12 20:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/12/2-stocks-to-buy-when-the-next-market-crash-comes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Roku (NASDAQ:ROKU) and Chewy (NYSE:CHWY) are two excellent companies growing revenue and customers rapidly. Investors have noticed, and their stock prices are up 289% and 154%, respectively, over the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/12/2-stocks-to-buy-when-the-next-market-crash-comes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CHWY":"Chewy, Inc.","ROKU":"Roku Inc"},"source_url":"https://www.fool.com/investing/2021/08/12/2-stocks-to-buy-when-the-next-market-crash-comes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158709252","content_text":"Roku (NASDAQ:ROKU) and Chewy (NYSE:CHWY) are two excellent companies growing revenue and customers rapidly. Investors have noticed, and their stock prices are up 289% and 154%, respectively, over the last three years.\nOne way you can get into these stocks at better prices would be during a stock market crash. Admittedly, it can be difficult to be a buyer when you see the market selling off. That's why it pays to look into companies you are interested in buying and put them on your list so that you can be ready to make the buy when the event occurs.\nHere are a few features of each stock that make these two companies attractive investments in the long run.\nData source: YCharts\n1. Roku\nRoku is benefiting from the long-run secular trend where consumers are switching from linear TV to streaming viewership. The rate of the shift may fluctuate but it's unlikely to change direction. According to Roku management, eventually, content will be 100% streaming. Indeed, here is what founder and CEO Anthony Wood said in its most recent conference call:\n\n But I think the big picture for me is that we're still in the middle of this transition where viewers, advertisers, and the industry is moving 100% to streaming. We're just not there yet, but it's moving and it's happening. If you look, one stat I think that's interesting from Nielsen is that if you look at 18 to 45-year-olds, 39% of their TV watching is streaming.\n\nRoku has accumulated 55.1 million accounts, a 28% increase from the second quarter of last year. Undoubtedly, the pandemic helped accelerate customer acquisition. Folks were limited in entertainment options when ballparks, concerts, restaurants, and movie theaters were all shut down for most of the previous year.\nThe company's operating system is reliable and fast. That's led many original equipment manufacturers to build TVs with Roku's operating system natively installed. Roku is the No. 1 TV operating system in the U.S. and Canada, and it's well on its way to international expansion.\nImage source: Getty Images.\n2. Chewy\nChewy is an exclusively online pet retailer. The company boasts 19.8 million active customers, 31.8% more than it had last year. The pandemic caused millions of pet parents to look for new options to fulfill their pet's everyday needs. Some may never return to shopping in brick-and-mortar stores. One reason is that Chewy offers customers automatic delivery of their pet's food and medicine.\nIndeed, in its most recent quarter, 69.3% of overall sales were through automatic delivery, or what Chewy calls Autoship. It makes people's lives easier as it is one less thing they need to remember. Chewy even offers a small discount on orders placed through Autoship. The company is piggybacking off the long-run spending moving online from retail locations.\nRevenue is growing rapidly, and Chewy is doing it efficiently. Its gross profit margin expanded from 16.6% in 2016 to 25.5% in 2021.\nInvestor takeaway\nRoku and Chewy are doing an excellent job capturing their respective markets and solving a problem for their customers. Streaming content costs less, and viewers get liberated from lengthy cable contracts. Chewy gives pet parents the peace of mind to know food and medicine can be delivered automatically.\nThe one hesitation investors could have with these two companies is their relatively rich valuations. Putting these stocks on your watch list and waiting for a market correction to buy could minimize that hesitation.","news_type":1},"isVote":1,"tweetType":1,"viewCount":255,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895994847,"gmtCreate":1628700074689,"gmtModify":1676529827020,"author":{"id":"3562228884568927","authorId":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3562228884568927","authorIdStr":"3562228884568927"},"themes":[],"htmlText":"If there is \"if only...\", then there will not be beggars...&nbsp;","listText":"If there is \"if only...\", then there will not be beggars...&nbsp;","text":"If there is \"if only...\", then there will not be beggars...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/895994847","repostId":"2158474560","repostType":4,"isVote":1,"tweetType":1,"viewCount":149,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896592259,"gmtCreate":1628591122471,"gmtModify":1703508682416,"author":{"id":"3562228884568927","authorId":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3562228884568927","authorIdStr":"3562228884568927"},"themes":[],"htmlText":"Wow... Visa is going to be affected by this for sure.&nbsp;","listText":"Wow... Visa is going to be affected by this for sure.&nbsp;","text":"Wow... Visa is going to be affected by this for sure.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/896592259","repostId":"2158761427","repostType":4,"isVote":1,"tweetType":1,"viewCount":1268,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":329807435,"gmtCreate":1615218260227,"gmtModify":1704779784726,"author":{"id":"3562228884568927","authorId":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3562228884568927","authorIdStr":"3562228884568927"},"themes":[],"htmlText":"Can we buy stocks that grow pot? I tried, but got rejected.&nbsp;","listText":"Can we buy stocks that grow pot? I tried, but got rejected.&nbsp;","text":"Can we buy stocks that grow pot? I tried, but got rejected.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/329807435","repostId":"1148943101","repostType":4,"repost":{"id":"1148943101","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1615206066,"share":"https://ttm.financial/m/news/1148943101?lang=&edition=fundamental","pubTime":"2021-03-08 20:21","market":"us","language":"en","title":"Canada eyes tighter rules for grow-your-own pot producers","url":"https://stock-news.laohu8.com/highlight/detail?id=1148943101","media":"Reuters","summary":"Canada’s health regulator will launch a public consultation program on Monday in its draft guidance ","content":"<p>Canada’s health regulator will launch a public consultation program on Monday in its draft guidance for individuals growing medical cannabis at home, hoping to clamp down on people selling weed on the black market.</p>\n<p>In the draft document sent to some industry figures and seen by Reuters ahead of publication, Health Canada highlights recent police raids and arrests at production sites where people were using licenses to “cover and support large-scale illegal production and sale”.</p>\n<p>The move also comes as Health Canada tries to set right a relatively unstable official market, where illegal sales are one factor undermining the business plans of the dozens of producers and distributors set up over the past five years.</p>\n<p>“Abuse of the medical purposes framework undermines the integrity of the system that many patients and health care practitioners rely on to access cannabis to address their medical needs,” Health Canada said in the document.</p>\n<p>The draft guidance for the first time sets out factors that the regulator may consider in refusing or revoking a registration for “personal production”. Factors include authorization of unjustified amounts and “criminal activity and/or diversion of cannabis”.</p>\n<p>Health Canada could not be immediately reached for comment.</p>\n<p>Canada in 2018 was the first major country to legalize cannabis but its programs have since run into a myriad of troubles.</p>\n<p>Households spent more than C$3.1 billion buying non-medical pot from illicit channels last year versus C$2.9 billion of legal purchases, according to Statistics Canada data.</p>\n<p>In January, Ontario Provincial Police seized over 180,000 cannabis plants and numerous vehicles and firearms by raiding illegal cultivation facilities, many of which exploit Health Canada’s personal medical weed cultivation licenses.</p>\n<p>Under the rules, people using cannabis for medical purposes must get a daily amount authorized by medical care practitioners - doctors, nurses and social workers - to either be bought from official retailers or grown personally.</p>\n<p>Health Canada said in December it was seeing a surge in the amount of pot personal cultivators were being authorized to grow.</p>\n<p>Personal cultivators are allowed to grow as much as 36 grams per day on average, compared with just 2 grams authorized for daily purchase from retailers.</p>\n<p>Health Canada will invite “interested stakeholders” to comment in the public consultation, expected to run for 60 days through May 7, with the aim of improving the programs’ operation and judging what factors it should consider when assessing risks to public health, the guidance said.</p>\n<p>After the end of the two-month period, the regulator plans to finalize the guidance and make it public.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Canada eyes tighter rules for grow-your-own pot producers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCanada eyes tighter rules for grow-your-own pot producers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-03-08 20:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Canada’s health regulator will launch a public consultation program on Monday in its draft guidance for individuals growing medical cannabis at home, hoping to clamp down on people selling weed on the black market.</p>\n<p>In the draft document sent to some industry figures and seen by Reuters ahead of publication, Health Canada highlights recent police raids and arrests at production sites where people were using licenses to “cover and support large-scale illegal production and sale”.</p>\n<p>The move also comes as Health Canada tries to set right a relatively unstable official market, where illegal sales are one factor undermining the business plans of the dozens of producers and distributors set up over the past five years.</p>\n<p>“Abuse of the medical purposes framework undermines the integrity of the system that many patients and health care practitioners rely on to access cannabis to address their medical needs,” Health Canada said in the document.</p>\n<p>The draft guidance for the first time sets out factors that the regulator may consider in refusing or revoking a registration for “personal production”. Factors include authorization of unjustified amounts and “criminal activity and/or diversion of cannabis”.</p>\n<p>Health Canada could not be immediately reached for comment.</p>\n<p>Canada in 2018 was the first major country to legalize cannabis but its programs have since run into a myriad of troubles.</p>\n<p>Households spent more than C$3.1 billion buying non-medical pot from illicit channels last year versus C$2.9 billion of legal purchases, according to Statistics Canada data.</p>\n<p>In January, Ontario Provincial Police seized over 180,000 cannabis plants and numerous vehicles and firearms by raiding illegal cultivation facilities, many of which exploit Health Canada’s personal medical weed cultivation licenses.</p>\n<p>Under the rules, people using cannabis for medical purposes must get a daily amount authorized by medical care practitioners - doctors, nurses and social workers - to either be bought from official retailers or grown personally.</p>\n<p>Health Canada said in December it was seeing a surge in the amount of pot personal cultivators were being authorized to grow.</p>\n<p>Personal cultivators are allowed to grow as much as 36 grams per day on average, compared with just 2 grams authorized for daily purchase from retailers.</p>\n<p>Health Canada will invite “interested stakeholders” to comment in the public consultation, expected to run for 60 days through May 7, with the aim of improving the programs’ operation and judging what factors it should consider when assessing risks to public health, the guidance said.</p>\n<p>After the end of the two-month period, the regulator plans to finalize the guidance and make it public.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNDL":"SNDL Inc.","TLRY":"Tilray Inc.","APHA":"Aphria Inc.","CRON":"Cronos Group Inc.","MJ":"Amplify Alternative Harvest ETF","ACB":"奥罗拉大麻公司","CGC":"Canopy Growth Corporation"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148943101","content_text":"Canada’s health regulator will launch a public consultation program on Monday in its draft guidance for individuals growing medical cannabis at home, hoping to clamp down on people selling weed on the black market.\nIn the draft document sent to some industry figures and seen by Reuters ahead of publication, Health Canada highlights recent police raids and arrests at production sites where people were using licenses to “cover and support large-scale illegal production and sale”.\nThe move also comes as Health Canada tries to set right a relatively unstable official market, where illegal sales are one factor undermining the business plans of the dozens of producers and distributors set up over the past five years.\n“Abuse of the medical purposes framework undermines the integrity of the system that many patients and health care practitioners rely on to access cannabis to address their medical needs,” Health Canada said in the document.\nThe draft guidance for the first time sets out factors that the regulator may consider in refusing or revoking a registration for “personal production”. Factors include authorization of unjustified amounts and “criminal activity and/or diversion of cannabis”.\nHealth Canada could not be immediately reached for comment.\nCanada in 2018 was the first major country to legalize cannabis but its programs have since run into a myriad of troubles.\nHouseholds spent more than C$3.1 billion buying non-medical pot from illicit channels last year versus C$2.9 billion of legal purchases, according to Statistics Canada data.\nIn January, Ontario Provincial Police seized over 180,000 cannabis plants and numerous vehicles and firearms by raiding illegal cultivation facilities, many of which exploit Health Canada’s personal medical weed cultivation licenses.\nUnder the rules, people using cannabis for medical purposes must get a daily amount authorized by medical care practitioners - doctors, nurses and social workers - to either be bought from official retailers or grown personally.\nHealth Canada said in December it was seeing a surge in the amount of pot personal cultivators were being authorized to grow.\nPersonal cultivators are allowed to grow as much as 36 grams per day on average, compared with just 2 grams authorized for daily purchase from retailers.\nHealth Canada will invite “interested stakeholders” to comment in the public consultation, expected to run for 60 days through May 7, with the aim of improving the programs’ operation and judging what factors it should consider when assessing risks to public health, the guidance said.\nAfter the end of the two-month period, the regulator plans to finalize the guidance and make it public.","news_type":1},"isVote":1,"tweetType":1,"viewCount":114,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":896592259,"gmtCreate":1628591122471,"gmtModify":1703508682416,"author":{"id":"3562228884568927","authorId":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3562228884568927","idStr":"3562228884568927"},"themes":[],"htmlText":"Wow... Visa is going to be affected by this for sure.&nbsp;","listText":"Wow... Visa is going to be affected by this for sure.&nbsp;","text":"Wow... Visa is going to be affected by this for sure.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/896592259","repostId":"2158761427","repostType":4,"repost":{"id":"2158761427","pubTimestamp":1628581266,"share":"https://ttm.financial/m/news/2158761427?lang=&edition=fundamental","pubTime":"2021-08-10 15:41","market":"sg","language":"en","title":"Amazon to introduce 0.5% surcharge for Visa credit card transactions in Singapore from Sept 15","url":"https://stock-news.laohu8.com/highlight/detail?id=2158761427","media":"The Straits Times","summary":"SINGAPORE - E-commerce giant Amazon has announced that it will impose a 0.5 per cent surcharge on Vi","content":"<div>\n<p>SINGAPORE - E-commerce giant Amazon has announced that it will impose a 0.5 per cent surcharge on Visa credit card transactions on its Singapore website, Amazon.sg, from Sept 15.\nAn Amazon spokesman ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/consumer/amazon-to-introduce-05-surcharge-for-visa-credit-card-transactions-in-singapore\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon to introduce 0.5% surcharge for Visa credit card transactions in Singapore from Sept 15</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon to introduce 0.5% surcharge for Visa credit card transactions in Singapore from Sept 15\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 15:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/singapore/consumer/amazon-to-introduce-05-surcharge-for-visa-credit-card-transactions-in-singapore><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SINGAPORE - E-commerce giant Amazon has announced that it will impose a 0.5 per cent surcharge on Visa credit card transactions on its Singapore website, Amazon.sg, from Sept 15.\nAn Amazon spokesman ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/consumer/amazon-to-introduce-05-surcharge-for-visa-credit-card-transactions-in-singapore\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"V":"Visa","AMZN":"亚马逊"},"source_url":"http://www.straitstimes.com/singapore/consumer/amazon-to-introduce-05-surcharge-for-visa-credit-card-transactions-in-singapore","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158761427","content_text":"SINGAPORE - E-commerce giant Amazon has announced that it will impose a 0.5 per cent surcharge on Visa credit card transactions on its Singapore website, Amazon.sg, from Sept 15.\nAn Amazon spokesman told The Straits Times that Singapore is the first country in the world where this surcharge will be imposed, but added that the high cost of accepting card payments is a global problem.\nThe spokesman said the surcharge will not apply to subscriptions, digital goods and services, as well as Amazon Fresh, the company's grocery delivery service.\nAn e-mail sent to users of Amazon.sg on Tuesday (Aug 10) attributed the surcharge to Visa's high cost of payments.\n\"To avoid this surcharge, we encourage you to use a debit or non-Visa credit card as the default payment method in your account,\" it added.\nThe Amazon spokesman also told ST that the cost of accepting card payments continues to be an obstacle to providing the best prices for customers.\n\"These costs should be going down over time with innovation and technological advancements, which allow merchants to reinvest savings into low prices and shopping enhancements for customers,\" he said.\n\"Yet, despite these advancements, some cards' cost of payments continues to stay high or even rise. As a result of Visa's continued high cost of payments, a surcharge is being added to Visa credit card payments in Singapore.\n\"With the rapidly changing payments landscape around the world, we anticipate a future that is less card-centric in the coming years, and we will continue innovating on behalf of customers to add and promote faster, cheaper and more inclusive payment options to our stores across the globe.\"\nST has contacted Visa for comment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1268,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894068067,"gmtCreate":1628778283459,"gmtModify":1676529852631,"author":{"id":"3562228884568927","authorId":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3562228884568927","idStr":"3562228884568927"},"themes":[],"htmlText":"I like chewy, but hesitant about Roku.&nbsp;I had their box previously, but didn't find it&nbsp;useful. A cheap android box from huaqiangbei is more than enough to replace Roku.&nbsp;","listText":"I like chewy, but hesitant about Roku.&nbsp;I had their box previously, but didn't find it&nbsp;useful. A cheap android box from huaqiangbei is more than enough to replace Roku.&nbsp;","text":"I like chewy, but hesitant about Roku. I had their box previously, but didn't find it useful. A cheap android box from huaqiangbei is more than enough to replace Roku.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/894068067","repostId":"2158709252","repostType":4,"isVote":1,"tweetType":1,"viewCount":255,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818599234,"gmtCreate":1630417869628,"gmtModify":1676530298114,"author":{"id":"3562228884568927","authorId":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3562228884568927","idStr":"3562228884568927"},"themes":[],"htmlText":"Regardless of the stock price, I do hope that this is finally a cure for Alzheimer disease. It is a crippling disease.&nbsp;","listText":"Regardless of the stock price, I do hope that this is finally a cure for Alzheimer disease. It is a crippling disease.&nbsp;","text":"Regardless of the stock price, I do hope that this is finally a cure for Alzheimer disease. It is a crippling disease.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/818599234","repostId":"1174676883","repostType":4,"repost":{"id":"1174676883","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630417268,"share":"https://ttm.financial/m/news/1174676883?lang=&edition=fundamental","pubTime":"2021-08-31 21:41","market":"us","language":"en","title":"AC Immune shares surged more than 70% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1174676883","media":"Tiger Newspress","summary":"AC Immune shares surged more than 70% in early trading.\n\n\nAC Immune SA and its collaborating partner","content":"<p>AC&nbsp;Immune&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;70%&nbsp;in&nbsp;early&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/9e1ae2e20dee3043b692297f3834cf6d\" tg-width=\"878\" tg-height=\"616\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><b>AC Immune SA</b>&nbsp;and its collaborating partner&nbsp;<b>Genentech</b>, part of&nbsp;<b>Roche Holdings AG</b>, have&nbsp;announced topline data&nbsp;from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).</li>\n <li>Semorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.</li>\n <li>Safety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.</li>\n <li>Semorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.</li>\n <li>There was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.</li>\n <li>Further analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.</li>\n <li>Semorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AC Immune shares surged more than 70% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAC Immune shares surged more than 70% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-31 21:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AC&nbsp;Immune&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;70%&nbsp;in&nbsp;early&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/9e1ae2e20dee3043b692297f3834cf6d\" tg-width=\"878\" tg-height=\"616\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><b>AC Immune SA</b>&nbsp;and its collaborating partner&nbsp;<b>Genentech</b>, part of&nbsp;<b>Roche Holdings AG</b>, have&nbsp;announced topline data&nbsp;from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).</li>\n <li>Semorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.</li>\n <li>Safety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.</li>\n <li>Semorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.</li>\n <li>There was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.</li>\n <li>Further analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.</li>\n <li>Semorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACIU":"AC Immune SA"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174676883","content_text":"AC Immune shares surged more than 70% in early trading.\n\n\nAC Immune SA and its collaborating partner Genentech, part of Roche Holdings AG, have announced topline data from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).\nSemorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.\nSafety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.\nSemorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.\nThere was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.\nFurther analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.\nSemorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.","news_type":1},"isVote":1,"tweetType":1,"viewCount":395,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895994847,"gmtCreate":1628700074689,"gmtModify":1676529827020,"author":{"id":"3562228884568927","authorId":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3562228884568927","idStr":"3562228884568927"},"themes":[],"htmlText":"If there is \"if only...\", then there will not be beggars...&nbsp;","listText":"If there is \"if only...\", then there will not be beggars...&nbsp;","text":"If there is \"if only...\", then there will not be beggars...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/895994847","repostId":"2158474560","repostType":4,"repost":{"id":"2158474560","pubTimestamp":1628687700,"share":"https://ttm.financial/m/news/2158474560?lang=&edition=fundamental","pubTime":"2021-08-11 21:15","market":"us","language":"en","title":"3 Tech Stocks That Turned $10,000 Into Over $500,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2158474560","media":"Motley Fool","summary":"These high-growth tech stocks generated massive multibagger gains.","content":"<p>The legendary investor Peter Lynch coined the term \"multibagger\" in his evergreen investing book <i>One Up on Wall Street</i>&nbsp;to describe stocks that have more than doubled in price. A stock that doubled in value was known as a \"two-bagger,\" while a stock that rose 20 times was called a \"20-bagger.\"</p>\n<p>Growth-oriented investors often seek out multibagger stocks in the tech sector, which has more than its fair share of high-growth and disruptive companies. It might seem tough to find the next big multibagger in this diverse sector, but studying a few stocks that previously crossed that threshold might help investors identify the upcoming winners.</p>\n<p>Let's examine three tech stocks that turned a modest $10,000 investment into more than $500,000 -- and what lessons we can glean from their massive multibagger gains.</p>\n<h2>1. Baidu: Turning $10,000 into more than $600,000</h2>\n<p><b>Baidu</b> (NASDAQ:BIDU), the Chinese tech company that owns the country's largest search engine, went public in 2005. If you had invested $10,000 in its IPO, your stake would be worth over $600,000 today.</p>\n<p>Between fiscal 2005 and 2010, Baidu's annual revenue rose at a whopping compound annual growth rate (CAGR) of 97.8%. The growth of the Chinese economy, rising income levels, and higher internet penetration rates drove that growth, and Baidu solidified its position as the online search leader in 2010 after <b>Alphabet</b>'s Google pulled out of mainland China.</p>\n<p>Between 2010 and 2015, Baidu's annual revenue grew at a CAGR of 53.6% as it expanded its ecosystem beyond its search engine with new mobile apps and cloud storage services.</p>\n<p>But between 2015 and 2020, Baidu's revenue only rose at a CAGR of 9.9%, as tighter restrictions on its online ads, rising competition from monolithic apps like <b>Tencent</b>'s WeChat, and the slowdown of China's economy throttled its growth. The pandemic exacerbated that pain last year, and Baidu remains exposed to the Chinese government's escalating crackdown on its top tech companies.</p>\n<p>As a result, Baidu's stock price has declined about 40% over the past six months and has stayed roughly flat over the past five years. That dismal return indicates high-growth multibagger stocks like Baidu can lose their momentum as their core markets mature, new competitors enter the market, and government regulators change the rules of the game.</p>\n<h2>2. Shopify: Turning $10,000 into nearly $900,000</h2>\n<p><b>Shopify</b> (NYSE:SHOP), a Canadian e-commerce services company that enables businesses to build their own online stores, fulfill their own orders, and manage their own marketing campaigns, went public in 2015. A $10,000 investment in its IPO would be worth nearly $900,000 today.</p>\n<p>Shopify grew like a weed because many smaller businesses didn't want to tether themselves to big online marketplaces like<b> Amazon</b> (NASDAQ:AMZN), which rein in their sellers with listing fees and restrictive rules. That transition accelerated throughout the pandemic last year as more businesses opened online stores.</p>\n<p>Shopify's revenue rose at a CAGR of 70.2% between 2015 and 2020. The stock has risen more than 30% this year, even as concerns about slower online spending in a post-pandemic market battered other e-commerce stocks -- and investors continue to pay a premium for Shopify's growth at over 40 times this year's sales.</p>\n<p>Unlike Baidu, Shopify doesn't yet face any existential challenges. Its decentralized e-commerce approach continues to disrupt Amazon's centralized platform, and it could have plenty of room to grow over the long term as more offline merchants bring their businesses online.</p>\n<h2>3. Nvidia: Turning $10,000 into $8.16 million</h2>\n<p><b>Nvidia</b> (NASDAQ:NVDA), the world's largest producer of discrete GPUs for computers, servers, and video game consoles, went public in 1999. If you had invested $10,000 in its IPO back then, your initial investment would now be worth nearly $8.2 million.</p>\n<p>Nvidia experienced a massive growth spurt over the past five years, as demand for its gaming and data center GPUs hit record levels. A new generation of PC games lifted sales of its gaming GPUs, while new AI applications at data centers sparked fierce demand for its high-end server GPUs.</p>\n<p>Higher cryptocurrency prices also periodically boosted sales of Nvidia's gaming GPUs for mining purposes, and it sold more Arm-based Tegra CPUs for connected cars and<b> Nintendo</b>'s Switch consoles.</p>\n<p>Those tailwinds, along with its acquisition of the data center equipment maker Mellanox last April, boosted Nvidia's annual revenue at a CAGR of 27.2% between fiscal 2016 and fiscal 2021.</p>\n<p>Nvidia remains <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the market's fastest-growing chipmakers, even as its proposed acquisition of Arm Holdings remains on thin ice. It continues to widen its lead against <b>Advanced Micro Devices </b>in the discrete GPU market, and it remains a solid investment on the secular growth of the gaming, data center, and AI markets.</p>\n<p>Nvidia's stock price has rallied more than 50% this year, yet its stock still looks surprisingly cheap at 12 times forward earnings. Therefore, Nvidia's stock could still have plenty of room to run -- even if the regulators strike down its ambitious takeover of Arm Holdings.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Tech Stocks That Turned $10,000 Into Over $500,000</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Tech Stocks That Turned $10,000 Into Over $500,000\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-11 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/3-tech-stocks-that-turned-10000-into-over-500000/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The legendary investor Peter Lynch coined the term \"multibagger\" in his evergreen investing book One Up on Wall Street to describe stocks that have more than doubled in price. A stock that doubled in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/3-tech-stocks-that-turned-10000-into-over-500000/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SHOP":"Shopify Inc","BIDU":"百度","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/08/10/3-tech-stocks-that-turned-10000-into-over-500000/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158474560","content_text":"The legendary investor Peter Lynch coined the term \"multibagger\" in his evergreen investing book One Up on Wall Street to describe stocks that have more than doubled in price. A stock that doubled in value was known as a \"two-bagger,\" while a stock that rose 20 times was called a \"20-bagger.\"\nGrowth-oriented investors often seek out multibagger stocks in the tech sector, which has more than its fair share of high-growth and disruptive companies. It might seem tough to find the next big multibagger in this diverse sector, but studying a few stocks that previously crossed that threshold might help investors identify the upcoming winners.\nLet's examine three tech stocks that turned a modest $10,000 investment into more than $500,000 -- and what lessons we can glean from their massive multibagger gains.\n1. Baidu: Turning $10,000 into more than $600,000\nBaidu (NASDAQ:BIDU), the Chinese tech company that owns the country's largest search engine, went public in 2005. If you had invested $10,000 in its IPO, your stake would be worth over $600,000 today.\nBetween fiscal 2005 and 2010, Baidu's annual revenue rose at a whopping compound annual growth rate (CAGR) of 97.8%. The growth of the Chinese economy, rising income levels, and higher internet penetration rates drove that growth, and Baidu solidified its position as the online search leader in 2010 after Alphabet's Google pulled out of mainland China.\nBetween 2010 and 2015, Baidu's annual revenue grew at a CAGR of 53.6% as it expanded its ecosystem beyond its search engine with new mobile apps and cloud storage services.\nBut between 2015 and 2020, Baidu's revenue only rose at a CAGR of 9.9%, as tighter restrictions on its online ads, rising competition from monolithic apps like Tencent's WeChat, and the slowdown of China's economy throttled its growth. The pandemic exacerbated that pain last year, and Baidu remains exposed to the Chinese government's escalating crackdown on its top tech companies.\nAs a result, Baidu's stock price has declined about 40% over the past six months and has stayed roughly flat over the past five years. That dismal return indicates high-growth multibagger stocks like Baidu can lose their momentum as their core markets mature, new competitors enter the market, and government regulators change the rules of the game.\n2. Shopify: Turning $10,000 into nearly $900,000\nShopify (NYSE:SHOP), a Canadian e-commerce services company that enables businesses to build their own online stores, fulfill their own orders, and manage their own marketing campaigns, went public in 2015. A $10,000 investment in its IPO would be worth nearly $900,000 today.\nShopify grew like a weed because many smaller businesses didn't want to tether themselves to big online marketplaces like Amazon (NASDAQ:AMZN), which rein in their sellers with listing fees and restrictive rules. That transition accelerated throughout the pandemic last year as more businesses opened online stores.\nShopify's revenue rose at a CAGR of 70.2% between 2015 and 2020. The stock has risen more than 30% this year, even as concerns about slower online spending in a post-pandemic market battered other e-commerce stocks -- and investors continue to pay a premium for Shopify's growth at over 40 times this year's sales.\nUnlike Baidu, Shopify doesn't yet face any existential challenges. Its decentralized e-commerce approach continues to disrupt Amazon's centralized platform, and it could have plenty of room to grow over the long term as more offline merchants bring their businesses online.\n3. Nvidia: Turning $10,000 into $8.16 million\nNvidia (NASDAQ:NVDA), the world's largest producer of discrete GPUs for computers, servers, and video game consoles, went public in 1999. If you had invested $10,000 in its IPO back then, your initial investment would now be worth nearly $8.2 million.\nNvidia experienced a massive growth spurt over the past five years, as demand for its gaming and data center GPUs hit record levels. A new generation of PC games lifted sales of its gaming GPUs, while new AI applications at data centers sparked fierce demand for its high-end server GPUs.\nHigher cryptocurrency prices also periodically boosted sales of Nvidia's gaming GPUs for mining purposes, and it sold more Arm-based Tegra CPUs for connected cars and Nintendo's Switch consoles.\nThose tailwinds, along with its acquisition of the data center equipment maker Mellanox last April, boosted Nvidia's annual revenue at a CAGR of 27.2% between fiscal 2016 and fiscal 2021.\nNvidia remains one of the market's fastest-growing chipmakers, even as its proposed acquisition of Arm Holdings remains on thin ice. It continues to widen its lead against Advanced Micro Devices in the discrete GPU market, and it remains a solid investment on the secular growth of the gaming, data center, and AI markets.\nNvidia's stock price has rallied more than 50% this year, yet its stock still looks surprisingly cheap at 12 times forward earnings. Therefore, Nvidia's stock could still have plenty of room to run -- even if the regulators strike down its ambitious takeover of Arm Holdings.","news_type":1},"isVote":1,"tweetType":1,"viewCount":149,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":329807435,"gmtCreate":1615218260227,"gmtModify":1704779784726,"author":{"id":"3562228884568927","authorId":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3562228884568927","idStr":"3562228884568927"},"themes":[],"htmlText":"Can we buy stocks that grow pot? I tried, but got rejected.&nbsp;","listText":"Can we buy stocks that grow pot? I tried, but got rejected.&nbsp;","text":"Can we buy stocks that grow pot? I tried, but got rejected.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/329807435","repostId":"1148943101","repostType":4,"isVote":1,"tweetType":1,"viewCount":114,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}